Inactive

The U. S. Food & Drug Administration, (FDA) Office of Acquisition and Grants Services (OAGS) has a requirement to procure a CDER-2023-118739 Biacore 1K+ upgrade kit- BNE -Brand Name or Equal, under so... The U. S. Food & Drug Administration, (FDA) Office of Acquisition and Grants Services (OAGS) has a requirement to procure a CDER-2023-118739 Biacore 1K+ upgrade kit- BNE -Brand Name or Equal, under solicitation FDA-RFQ-CDER-2023-118739-BNE. To continue to support the FDA mission, CDER is seeking to expand its current label-free Biacore surface plasmon resonance (SPR) systems. The system shall be able to identify and measure molecular interactions of drugs and their biological receptors in a highly quantitative manner. FDA is looking to purchase a Biacore 1K+ SPR system upgrade with enhanced capabilities over the current Biacore T200 SPR, and which uses advanced intuitive software that will allow enhanced evaluation of SPR data to include interactive runs, potency assessments, and multi-complex analyses using poly-injections. FDA seeks to purchase a BRAND NAME OR EQUIVALENT Biacore 1K+ SPR system upgrade.